Amcor plc (AMCR) Stock Price & How to Invest

Amcor plc makes the packaging most shoppers touch every day without noticing: the film around fresh meat and cheese, the pouch holding pet food, blister and sterile packs for medicines, PET bottles for soft drinks, and plastic containers for food service and beauty products. Founded in Australia in 1926 and now headquartered in Zurich, it listed on the NYSE in 2019 after buying Bemis, and in April 2025 it closed an all-stock merger with Berry Global that roughly doubled its rigid plastics business. The combined company employs about 75,000 people and reports in two segments, Global Flexible Packaging Solutions and Global Rigid Packaging Solutions. In January 2026 it completed a one-for-five reverse stock split, so today's ~$46 share price is not comparable to the ~$10 quotes from 2025.

Fiscal 2026, which ended June 30, 2026, was the first full year with Berry inside. Net sales rose ~57% to ~$23.5 billion, adjusted EBIT rose ~63% to ~$2.8 billion, and adjusted EPS rose ~13% to ~$4.02, at the top of the company's own range. GAAP EPS was ~$2.38, held down by integration, restructuring and amortization charges. The fourth quarter was the strongest of the year: adjusted EPS of ~$1.23 (up ~23%), and volumes turned slightly positive after several quarters of declines. Synergies reached ~$285 million, about 10% ahead of plan. The weak spot was cash: free cash flow of ~$1.3 billion came in roughly $200 million below the outlook, as a Middle East conflict drove up resin prices and tied up ~$500 million of working capital. Amcor is moving to a December year-end, and has guided ~$1.80 to ~$1.90 of adjusted EPS for the six-month transition period ending December 31, 2026.

The investment picture is a classic integration story priced cheaply. At ~$46 the market cap is ~$21.3 billion, and with ~$12.9 billion of net debt the enterprise value is ~$34 billion. The stock sits below its February high of ~$50.94 but well above its May low of ~$36.25. Investors are weighing a ~5.6% dividend yield and management's call for double-digit adjusted EPS growth in calendar 2027 against leverage of ~3.5x, years of flat-to-negative organic volumes, and a former Berry shareholder base that has seen the stock fall since the deal closed.

Leverage is the central risk. With ~$12.9 billion of net debt and leverage near ~3.5x, a stumble in earnings or cash flow would slow deleveraging and could pressure the dividend, which already absorbs roughly half of the ~$2.5 billion free cash flow management is guiding to. Higher interest and tax expense is already a ~$0.10 to ~$0.12 per share headwind in the transition period. Resin and input costs are a second exposure: Middle East disruption in 2026 drove what management called unprecedented inflation, and while Amcor passed through ~$280 million of price in the June quarter, pass-through lags can squeeze margins and tie up working capital, as the ~$500 million build showed. Volumes have been weak for years, especially in healthcare (lower-margin categories), North American beverage, and liquids, and the recent turn is only one quarter old. Integration execution matters too, since the 2027 EPS growth call leans heavily on synergies. Regulatory pressure on single-use plastics, including EU packaging rules and extended producer responsibility fees, could raise costs or shift demand toward paper and reusable formats. Finally, law firms have advertised investigations on behalf of former Berry holders, though no securities class action had been filed as of October 2026.

11 analysts publish price targets on AMCR, averaging $50.29 against a $46.23 price as of October 2026, or +8.8%. The published targets run from $42.00 to $60.00, a moderate spread, and the ratings split 7 buy, 6 hold, 0 sell. Over the last six months there have been 6 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMCR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Amcor plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Berry Global synergies. The single biggest lever is cost and revenue synergy from the Berry merger. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. Leverage is the central risk. The most pessimistic target, $42.00, is roughly what AMCR is worth if this bites instead.

Read the full bull and bear case on AMCR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amcor plc's investor relations page or your broker.

• Revenue (FY2026, to June): ~$23.5B
• Adjusted EPS (FY2026): ~$4.02
• P/E (adjusted / GAAP): ~11.5x / ~19x
• Market cap: ~$21.3B
• Dividend yield: ~5.6% ($2.60/yr)
• Net debt / leverage: ~$12.9B / ~3.5x

At ~$46.17 on October 26, 2026, Amcor trades at ~11.5x fiscal 2026 adjusted EPS of ~$4.02 and ~19x GAAP EPS of ~$2.38, the gap reflecting merger amortization and restructuring charges. Enterprise value is ~$34 billion, or roughly 9x EBITDA. The ~5.6% dividend yield is high for a large-cap industrial. That discount reflects leverage, years of soft volumes and scepticism about synergy delivery. Guidance of ~$1.80 to ~$1.90 for the six months to December and double-digit growth in calendar 2027 would, if met, bring the forward multiple closer to ~10x.

Other names that sit close to AMCR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AMCR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMCR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMCR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Amcor is a high-yield, low-multiple packaging giant whose next two years depend on delivering ~$650M of Berry synergies, recovering volumes and bringing leverage from ~3.5x toward ~3x by end-2027.

Whether AMCR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMCR a buy or a sell?, and where the stock could go from here in the AMCR stock forecast.

For income investors, whether AMCR pays a dividend and how the payout looks is covered in does AMCR pay a dividend? And to weigh AMCR against a peer, read the full side-by-side comparisons: AMCR vs SLGN and AMCR vs ATR.